LB Pharmaceuticals

tenant

drug

Magnetic Seizure Therapy (MagPro MST)

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

DEVICE

Pre-approval / investigational in the US

Developed by Centre for Addiction and Mental Health

1 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

DEVICE

Indications

Investigational (via trials)

Schizophrenia Obsessive-Compulsive Disorder Schizophrenia Schizophrenia, Treatment-Resistant Depressive Disorder Depressive Disorder, Treatment-Resistant Obsessive-Compulsive Disorder Depressive Disorder Psychotic Disorders Schizoaffective Disorder

Trials

1

Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder

NCT01596608—Completed

KOLs & investigators

1

Z. Jeffrey Daskalakis, MD, PhD.KOL score 5

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

Centre for Addiction and Mental Health

company

trial

Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder

NA

trial

indication

indication

Obsessive-Compulsive Disorder

indication

indication

Schizophrenia, Treatment-Resistant

indication

KOL

Z. Jeffrey Daskalakis, MD, PhD.

KOL score 5

person